Kim Jae Hak, Cheon Jae Hee, Kim Won Ho
Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea.
Korean J Gastroenterol. 2008 May;51(5):291-7.
BACKGROUND/AIMS: This study was to evaluate the frequency and the course of the adverse effects of AZA/6-MP in Korean patients with inflammatory bowel disease (IBD).
Medical records of the patients with IBD treated with AZA/6-MP at Severance hospital from June 1996 to September 2006 were retrospectively analyzed.
A total of 133 patients were studied. Male to female ratio was 1.3:1. The mean age was 31.7+/-10.9 year. Adverse effects included leukopenia occurred in 75 cases (56.4%), nausea/vomiting in 32 cases (24.1%), arthralgia in 6 cases (4.5%), hepatitis in 6 cases (4.5%), skin rash in 4 cases (3.0%), herpes zoster in 3 cases (2.3%), and headache in 1 case (0.8%). Most of leucopenia (58.7%) developed within 3 months after maximal tolerated dose of AZA/6-MP and nausea/vomiting frequently occurred within 3 months after start of AZA/6-MP treatment. Thirty-eight patients (28.6%) required the discontinuation of medication due to adverse effects.
Leukopenia was the most common adverse effect of AZA/6-MP treatment. Leukopenia and nausea/vomiting developed frequently in the early period of treatment of AZA/6-MP in patients with IBD. AZA/6-MP should be used cautiously to scrutinize bone marrow suppression.
背景/目的：本研究旨在评估韩国炎症性肠病（IBD）患者使用硫唑嘌呤（AZA）/6-巯基嘌呤（6-MP）的不良反应发生率及病程。
回顾性分析1996年6月至2006年9月在Severance医院接受AZA/6-MP治疗的IBD患者的病历。
共研究了133例患者。男女比例为1.3:1。平均年龄为31.7±10.9岁。不良反应包括75例（56.4%）发生白细胞减少，32例（24.1%）出现恶心/呕吐，6例（4.5%）有关节痛，6例（4.5%）有肝炎，4例（3.0%）出现皮疹，3例（2.3%）有带状疱疹，1例（0.8%）有头痛。大多数白细胞减少（58.7%）在AZA/6-MP最大耐受剂量后3个月内出现，恶心/呕吐常在AZA/6-MP治疗开始后3个月内频繁发生。38例患者（28.6%）因不良反应需要停药。
白细胞减少是AZA/6-MP治疗最常见的不良反应。IBD患者在AZA/6-MP治疗早期常出现白细胞减少和恶心/呕吐。使用AZA/6-MP时应谨慎，仔细检查骨髓抑制情况。
